|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RNASE1 |
Gene summary for RNASE1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RNASE1 | Gene ID | 6035 |
| Gene name | ribonuclease A family member 1, pancreatic | |
| Gene Alias | RAC1 | |
| Cytomap | 14q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P07998 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6035 | RNASE1 | HTA12-25-1 | Human | Pancreas | PDAC | 9.37e-05 | -9.91e-01 | 0.313 |
| 6035 | RNASE1 | HTA12-26-1 | Human | Pancreas | PDAC | 1.22e-06 | -9.91e-01 | 0.3728 |
| 6035 | RNASE1 | HTA12-29-1 | Human | Pancreas | PDAC | 6.62e-21 | -9.75e-01 | 0.3722 |
| 6035 | RNASE1 | HTA12-9-3 | Human | Pancreas | PDAC | 2.48e-03 | -9.91e-01 | 0.2045 |
| 6035 | RNASE1 | 3829-EC | Human | Pancreas | PanIN | 1.79e-08 | -5.52e-02 | 0.009 |
| 6035 | RNASE1 | 4347-EC | Human | Pancreas | PanIN | 2.39e-15 | -4.29e-01 | 0.0572 |
| 6035 | RNASE1 | DS20191261Tumor | Human | Pancreas | PDAC | 1.41e-10 | -8.88e-01 | 0.1367 |
| 6035 | RNASE1 | Pat01-B | Human | Stomach | GC | 5.75e-32 | -6.22e-01 | 0.5754 |
| 6035 | RNASE1 | Pat02-B | Human | Stomach | GC | 5.68e-46 | -4.35e-01 | 0.0368 |
| 6035 | RNASE1 | Pat03-B | Human | Stomach | GC | 4.41e-23 | -4.46e-01 | 0.3693 |
| 6035 | RNASE1 | Pat04-B | Human | Stomach | GC | 3.78e-30 | -1.10e-01 | -0.1483 |
| 6035 | RNASE1 | Pat05-B | Human | Stomach | GC | 2.58e-09 | -1.16e-01 | -0.0353 |
| 6035 | RNASE1 | Pat06-B | Human | Stomach | GC | 2.19e-40 | 2.64e-01 | -0.1961 |
| 6035 | RNASE1 | Pat07-B | Human | Stomach | GC | 1.62e-08 | -8.64e-01 | 0.0935 |
| 6035 | RNASE1 | Pat08-B | Human | Stomach | GC | 1.02e-02 | -3.21e-01 | 0.0182 |
| 6035 | RNASE1 | Pat09-B | Human | Stomach | GC | 6.25e-17 | -7.74e-01 | -0.0359 |
| 6035 | RNASE1 | Pat11-B | Human | Stomach | GC | 6.87e-18 | 2.71e-01 | -0.182 |
| 6035 | RNASE1 | Pat12-B | Human | Stomach | GC | 1.75e-27 | -5.73e-01 | 0.0325 |
| 6035 | RNASE1 | Pat13-B | Human | Stomach | GC | 3.84e-12 | -7.05e-01 | 0.0555 |
| 6035 | RNASE1 | Pat15-B | Human | Stomach | GC | 3.21e-07 | -2.94e-02 | -0.0778 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00905013 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
| GO:00905023 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis, endonucleolytic | 55/8552 | 82/18723 | 7.34e-05 | 5.51e-04 | 55 |
| GO:0090501 | Liver | Cirrhotic | RNA phosphodiester bond hydrolysis | 54/4634 | 152/18723 | 1.89e-03 | 1.19e-02 | 54 |
| GO:00905011 | Liver | HCC | RNA phosphodiester bond hydrolysis | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
| GO:0090305 | Liver | HCC | nucleic acid phosphodiester bond hydrolysis | 152/7958 | 261/18723 | 1.90e-07 | 3.46e-06 | 152 |
| GO:0090502 | Liver | HCC | RNA phosphodiester bond hydrolysis, endonucleolytic | 52/7958 | 82/18723 | 1.06e-04 | 9.08e-04 | 52 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RNASE1 | SNV | Missense_Mutation | c.464C>G | p.Ser155Cys | p.S155C | P07998 | protein_coding | deleterious_low_confidence(0) | benign(0.299) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| RNASE1 | SNV | Missense_Mutation | novel | c.152N>T | p.Ser51Phe | p.S51F | P07998 | protein_coding | deleterious(0.01) | possibly_damaging(0.76) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| RNASE1 | SNV | Missense_Mutation | novel | c.199C>T | p.Arg67Trp | p.R67W | P07998 | protein_coding | tolerated(0.32) | benign(0) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| RNASE1 | SNV | Missense_Mutation | c.41N>C | p.Val14Ala | p.V14A | P07998 | protein_coding | tolerated(0.42) | probably_damaging(0.93) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RNASE1 | SNV | Missense_Mutation | c.286N>T | p.Gly96Trp | p.G96W | P07998 | protein_coding | deleterious(0.01) | benign(0.127) | TCGA-B5-A11J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RNASE1 | insertion | In_Frame_Ins | novel | c.94_95insAGCTGATGTTTGCCT | p.Arg32delinsGlnLeuMetPheAlaTrp | p.R32delinsQLMFAW | P07998 | protein_coding | TCGA-B5-A11F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD | ||
| RNASE1 | insertion | Frame_Shift_Ins | novel | c.376_377insAGGGAAGGCTGGACCCAGCCCAGCACCAGCAGTATCA | p.Arg126GlnfsTer26 | p.R126Qfs*26 | P07998 | protein_coding | TCGA-B5-A11I-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD | ||
| RNASE1 | SNV | Missense_Mutation | c.160N>C | p.Cys54Arg | p.C54R | P07998 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-ED-A66Y-01 | Liver | liver hepatocellular carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| RNASE1 | SNV | Missense_Mutation | novel | c.440N>G | p.His147Arg | p.H147R | P07998 | protein_coding | deleterious(0.01) | probably_damaging(0.949) | TCGA-63-7021-01 | Lung | lung squamous cell carcinoma | Male | Unknown | I/II | Unknown | Unknown | PD |
| RNASE1 | SNV | Missense_Mutation | rs1804215 | c.200G>T | p.Arg67Leu | p.R67L | P07998 | protein_coding | tolerated(0.6) | benign(0.046) | TCGA-CR-7385-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6035 | RNASE1 | DRUGGABLE GENOME | CYTIDINE 3'-PHOSPHATE | CHEMBL258728 | 18226913 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |